11:24 AM EDT, 07/18/2024 (MT Newswires) -- Pluri ( PLUR ) shares rose said 7.3% in recent Thursday trading after the company's contract development and manufacturing organization signed a tech transfer and manufacturing agreement to make cell therapy product candidates AstroRx and IsletRx for Kadimastem.
The companies are based in Israel. Financial terms weren't disclosed.
AstroRx is designed for the treatment of amyotrophic lateral sclerosis, and IsletRx aims to treat diabetes, Pluri ( PLUR ) said Thursday in a statement.
Price: 5.75, Change: +0.39, Percent Change: +7.27